The progression from MDS to AML in older adults, or following chemotherapy, is an important clinical model for the study of carcinogenesis. The long latent period from exposure to development of disease, and the gradual evolution from pre-MDS, to MDS, to AML, argues strongly in favor of a multi-step process f carcinogenesis in which tumor suppressor gene (TSG's) are implicated. The complex karyotypes observed in these disorders usually involve chromosomal loss or deletions further reinforcing the concept of TSG's . Among the deletions in our clinical series, 5q, 7q, and 20q are consistently seen and are associated with specific clinical features suggesting the presence of TSG's. Our long term goal has been to identify these genes with a particular emphasis on 5q; continued deletion mapping and clinical correlations will further this goal. This is addressed in the first two Specific Aims: 1) To better delineate the chromosomal regions implicated for tumor suppressor genes on 5q, 7q, and 20q and to correlate them with clinical features. 2) When the del(5q) TSG is identified in a parallel project, to identify mutations in individual cases, characterize their structure-function relationships, and correlate with disease features. A secondary goal of our project involves the analysis of the MADR5 gene which we identified as a potential TSG. We believe that MADR5 and related genes play a critical role in signaling by TGF-beta, an inhibitory pathway that has only recently been recognized in the regulation of normal hematopoiesis, and is often disrupted in MDS-AML. The TGF-beta signaling pathway has not been studied in myeloid cells. Thus our last two aims are: 3) To elucidate the mechanics of TGF-beta signaling via MAD%5 and related genes in normal hematopoiesis; and 4) To determine the role of TGF-beta signaling in leukemogenesis, emphasizing cases with demonstrated TGF-beta resistance. These studies will help us to identify new TSG's in MDS-AML and understand their clinical significance, and may provide insight into their therapeutic manipulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA075606-02
Application #
6269876
Study Section
Project Start
1998-08-31
Project End
1999-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Raza, A; Candoni, A; Khan, U et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45:2099-104
Candoni, Anna; Silvestri, Federico; Buonamici, Silvia et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41:13-20
Raza, Azra; Buonamici, Silvia; Lisak, Laurie et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791-803
Gladstone, Betty; Sivaraman, Smitha; Galili, Naomi et al. (2003) A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res 27:529-37
Huang, X K; Meyer, P; Li, B et al. (2003) The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. Leuk Lymphoma 44:157-64
Reddy, Poluru L; Shetty, Vilasini T; Dutt, Diya et al. (2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 116:564-75
Allampallam, Krishnan; Shetty, Vilasini; Mundle, Suneel et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-97
Shetty, Vilasini; Hussaini, Seema; Alvi, Sairah et al. (2002) Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol 116:817-25
Zorat, F; Shetty, V; Dutt, D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115:881-94
Preisler, H D (2001) Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treat Res 108:185-230

Showing the most recent 10 out of 40 publications